HOT PRODUCT | LOW STOCK

Tirzepatide (5mg)

Name: Tirzepatide (5mg)
SKU: SKU003
Availability: InStock

$120.00

Science Backed

High Quality

Secure & Reliable

Research use only, not for human or animal use.

This is the extra content added to the product description.

Overview

Tirzepatide is a novel unimolecular dual agonist targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This innovative mechanism leverages the synergistic effects of the two incretin hormones to improve glycemic control and facilitate weight loss. Clinical studies, such as the SURPASS trials for type 2 diabetes and the SURMOUNT trials for obesity, have demonstrated its efficacy in significantly reducing HbA1c levels and promoting substantial weight loss. Source: Scheen, A., 2024, PubMed

The Best Research Peptides.

asdfThe Best Research Peptides.

The Best Research Peptides.

Guide to Tirzepatide

1. What Is Tirzepatide

2. Tirzepatide Structure

3. Tirzepatide Research

4. Referenced Citations

What is Tirzepatide?

Tirzepatide is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, designed to improve glycemic control in individuals with type 2 diabetes. Its mechanism of action includes enhancing insulin secretion, reducing glucose levels, and aiding in weight management. Recent research has also highlighted its potential in addressing complications such as diabetic nephropathy by targeting oxidative stress through the PI3K/AKT signaling pathway (Source: International Immunopharmacology, 2024).

Blank vaccine label on injection glass bottle with green liquid

Tirzepatide Peptide Structure

Sequence: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe
Molecular Formula: C78H125N23O23S2
Molecular Weight: 1817.12 g/mol
CAS Number: 66004-57-7

Tirzepatide Research

1. Mechanism of Action of Tirzepatide

Tirzepatide is a dual receptor agonist targeting glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. By activating both receptors, Tirzepatide enhances insulin secretion, reduces glucagon levels, and slows gastric emptying. These mechanisms improve glycemic control and contribute to significant weight reduction. Unlike traditional GLP-1 receptor agonists, Tirzepatide’s dual action offers a synergistic effect, making it a promising therapy for managing type 2 diabetes and obesity.

2. Tirzepatide in Cardiovascular Risk Reduction

In clinical trials, Tirzepatide has shown remarkable potential in promoting weight loss. Studies demonstrate that patients using Tirzepatide achieved average weight reductions of up to 22.5% of their baseline weight over 72 weeks. This outcome surpasses existing anti-obesity medications, making Tirzepatide a groundbreaking therapy in weight management. The drug’s ability to target hunger regulation and energy expenditure through its dual agonist mechanism is central to its efficacy.

3. Tirzepatide in Cardiovascular Risk Reduction

Beyond glycemic and weight management, Tirzepatide has demonstrated significant potential in reducing cardiovascular risks. Clinical data show that Tirzepatide lowers markers such as LDL cholesterol and blood pressure, which are critical in preventing cardiovascular complications in patients with diabetes. This dual benefit positions Tirzepatide as a comprehensive treatment option for improving metabolic and cardiovascular health outcomes.

4. Future Research on Tirzepatide

Future studies should focus on the long-term safety profile of Tirzepatide and its effects on non-metabolic diseases such as fatty liver disease and polycystic ovary syndrome (PCOS). Researchers are also exploring whether Tirzepatide’s dual agonist mechanism can be extended to treat neurodegenerative conditions like Alzheimer’s disease, as incretin pathways have shown promise in early studies. Finally, personalized medicine approaches may optimize dosing for diverse populations to maximize benefits while minimizing risks.

Article Author

Dr. J. P. Frías and colleagues are prominent researchers behind key Tirzepatide studies. Their groundbreaking work, published in The New England Journal of Medicine, demonstrated Tirzepatide’s unique dual receptor agonist mechanism, which effectively improves glycemic control and promotes significant weight loss in individuals with type 2 diabetes. Additionally, Dr. A. M. Jastreboff’s team explored Tirzepatide’s potential for obesity management, showing its ability to achieve substantial weight reductions. Further, Dr. J. Rosenstock’s cardiovascular studies revealed that Tirzepatide not only improves metabolic outcomes but also reduces cardiovascular risks in patients with type 2 diabetes. These findings underscore the compound’s promising versatility. Lastly, Dr. M. A. Nauck discussed future research directions, suggesting potential applications of Tirzepatide beyond metabolic conditions, such as in neurodegenerative diseases. These contributions collectively highlight the extensive research and development efforts shaping Tirzepatide as a groundbreaking therapeutic option.

Scientific Journal Author

In 1986 Professor Jens Juul Holst discovered the GLP-1 hormone in connection with his work on stomach ulcer surgery. Since the

discovery, Novo Nordisk have used the research to successfully develop products to treat diabetes and obesity. The hormone GLP-1 can be used to regulate blood sugar levels and satiety. Not only has it made treatment of obesity and diabetes possible, it has also proven useful preventatively through early diagnosis for citizens who are at risk of developing diabetes and obesity. In 2015, Jens Juul Holst received the prestigious international Fernström prize for his research on GLP-1. He is one of the most cited researchers in Europe, with over 1,200 published articles and citations in over 3,500 articles annually.

Professor Jens Juul Holst is being referenced as one of the leading scientists involved in the research and development of GLP-1. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Peptide Sciences and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this

Referenced Citations

1

Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021). “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” New England Journal of Medicine, 385(6), 503–515. DOI:10.1056/NEJMoa2107519

2

Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Shringarpure, R. (2022). “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine, 387(3), 205–216. DOI:10.1056/NEJMoa2206038

3

Rosenstock, J., Wysham, C., Frias, J. P., Kaneko, S., Lee, C. J., Kaneshiro, T., Surve, S., Ruan, X., & Unger, J. (2019). “Efficacy and Safety of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, in Patients with Type 2 Diabetes (SURPASS-1): A Double-Blind, Randomised, Phase 3 Trial.” The Lancet Diabetes & Endocrinology, 9(8), 511–520. DOI:10.1016/S2213-8587(21)00122-5

4

F. M. Ng, J. Sun, L. Sharma, R. Libinaka, W. J. Jiang, and R. Gianello, “Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone,” Horm. Res., vol. 53, no. 6, pp. 274-278, 2000.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.

The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.

FAQs, Answered.

What are peptides?

Peptides are short chains of amino acids ranging from 2-50 amino acids linked together by peptide bonds. They are smaller than proteins, which are made up of longer chains of amino acids. Peptides occur naturally in the body and play an important role in biological functions such as signaling, immune responses and tissue repair.

How do peptides work?

Peptides work in various ways depending on their type and structure. Some peptides act as hormones, such as insulin, which regulates blood sugar. Others function as neurotransmitters, sending signals between nerve cells.

They can also help in regulating immune responses, healing wounds, or promoting the production of proteins like collagen.

Where to buy top-quality peptides online?